친구들에게,
지난 두 달 건강이 또 좋지 않았습니다(이 자유게시판 No. 196, 92 참조). 아래의 서신에 관련된 이야기가 있습니다. 참고 바랍니다.
서울대 이장규 교수(전기공학부)가 보내준 심장마비 대비책 파일을 꼭 보세요! 나로서는 파일 uploading을 우리 홈페이지에 할 수 없으니 내 홈페이지 http://angels.snu.ac.kr News No. 205의 파일(심장박동이_갑자기_정지했다ppt)을 열어요.
내 건강이 허락한다면 내주 수요일 동창회에 참석할 것입니다.
더욱 건강하세요.
註] 최창균 홈페이지는 최창균 정년퇴임에 따라 없어졌음
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
O 교수,
잘 있으리라고 믿네.
나는 지난 3월2일에 다시 반포로 이사하였네. 그후 계속 당뇨(diabetes)+SAD(아래 FDA News 참조) 증세로 힘들어 하다가 오늘 밤 12시55분에 일어나서 두 달여만에 처음으로 새벽에 12000보 정도를 걷고 아침 7시에 학교 사무실에 와서 이 글을 쓰고 있네.
----------------------------------------
----------------------------------------
FDA News
FOR IMMEDIATE RELEASE
P06-79
June 12, 2006
Media Inquiries:
Kimberly Rawlings , 301-827-6242
Consumer Inquiries:
888-INFO-FDA
FDA Approves the First Drug for Seasonal Depression
The Food and Drug Administration (FDA) today approved Wellbutrin XL for prevention of major depressive episodes in patients with a history of seasonal affective disorder (SAD). This is the first drug approved for SAD. Wellbutrin XL (bupropion HCL extended release tablets) previously was approved for treatment of major depressive disorder.
SAD is characterized by recurrent major depressive episodes that usually coincide with the seasonal decrease of daylight during autumn and winter. The depressive episodes can last up to 6 months. Although patients with SAD may have depressive episodes during other times of the year, the diagnosis of seasonal affective disorder requires that the number of seasonal episodes substantially outnumber the non-seasonal episodes during the individual's lifetime.
A major depressive episode is defined as the presence of 5 or more of the 9 core symptoms of major depression for at least 2 weeks. The symptoms include: depressed mood; loss of interest; weight loss (or other weight or appetite changes); insomnia or hypersomnia; agitation or psychomotor retardation; fatigue; feelings of worthlessness or guilt; impaired concentration; suicidal thinking or behavior. One of the 5 symptoms must be either depressed mood or loss of interest in activities. Another essential feature of major depression is the presence of significant distress or impairment in social, occupational, or other important areas of functioning. A seasonal major depressive episode is defined by the identical features.
“Seasonal affective disorder can significantly impair the quality of life of patients with this condition,” said Dr. Steven Galson, Director for FDA’s Center of Drugs and Research. “Today’s approval can help patients with this condition to avoid the depressive symptoms and impaired functioning that typically affect them in the fall and winter.”
The effectiveness of Wellbutrin XL for the prevention of SAD episodes was established in 3 double-blind, placebo-controlled trials in adults with a history of major depressive disorder in autumn and winter. Treatment was initiated prior to the onset of symptoms in the autumn (September to November) and was discontinued following a two-week taper that began the first week of spring (fourth week of March). In these trials, the percentage of patients who were depression-free at the end of treatment was significantly higher for those on Wellbutrin XL than for those on placebo; for all 3 studies combined, the overall rate of patients depression-free at the end of treatment was 84 percent for those on Wellbutrin XL compared to 72 percent for those on placebo.
Wellbutrin XL’s labeling includes a “black box” warning concerning the increased risk of suicidal thoughts and behavior in pediatric patients treated with antidepressant medications. As with all antidepressants, Wellbutrin XL has a Medication Guide (MedGuide, or patient labeling) advising that pediatric patients on antidepressants should be watched closely for these serious symptoms. Important side effects to watch for with Wellbutrin XL, especially shortly after the initiation of the treatment, include agitation, anxiety and insomnia. Wellbutrin was safe and well tolerated by patients in the SAD trials.
It is important to note that Wellbutrin XL is indicated only for patients who meet strict diagnostic criteria of seasonal major depressive episodes. Such patients have a pattern of recurrent, clinically significant depressive symptoms with associated impairment of functioning. The clinician and patient should carefully assess the potential risks and benefits when considering treatment with Wellbutrin XL for SAD.
Wellbutrin XL is manufactured by GlaxoSmithKline.
------------------------------------------------
------------------------------------------------
내가 찾은, 위의 뉴스에 나오는 9개의 SAD증세 중 나는 7개의 증상(depressed mood; loss of interest; weight or appetite changes; hypersomnia; psychomotor retardation; fatigue; feelings of worthlessness; impaired concentration)을 보이네. 그렇다고 내가 SAD환자라는 이야기는 아니네. 내가 의사의 진단을 존중한다는 것을 또 이야기 하네. 한 자료에 의하면 미국에 약50만의 SAD환자가 있다고 하네.
위와 같은 연유로 내가 이 서신의 제목에 "D+SAD"[내가 작명]를 넣은 것이네. 지난 달 서울대병원 혈액검사 결과는 투약의 강도에 반비례하여 혈당과 체중은 다소 증가한 상태이네. SAD 탓일까?
좋은 조언 부탁하네. 작은 성의로 심장관련 파일 하나 보내네.
다음에 서울대병원 방문시에 내가 점심을 대접할 수 있도록 시간을 할애하여 주면 고맙겠네. 연락하겠네.
최창균
지난 두 달 건강이 또 좋지 않았습니다(이 자유게시판 No. 196, 92 참조). 아래의 서신에 관련된 이야기가 있습니다. 참고 바랍니다.
서울대 이장규 교수(전기공학부)가 보내준 심장마비 대비책 파일을 꼭 보세요! 나로서는 파일 uploading을 우리 홈페이지에 할 수 없으니 내 홈페이지 http://angels.snu.ac.kr News No. 205의 파일(심장박동이_갑자기_정지했다ppt)을 열어요.
내 건강이 허락한다면 내주 수요일 동창회에 참석할 것입니다.
더욱 건강하세요.
註] 최창균 홈페이지는 최창균 정년퇴임에 따라 없어졌음
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
O 교수,
잘 있으리라고 믿네.
나는 지난 3월2일에 다시 반포로 이사하였네. 그후 계속 당뇨(diabetes)+SAD(아래 FDA News 참조) 증세로 힘들어 하다가 오늘 밤 12시55분에 일어나서 두 달여만에 처음으로 새벽에 12000보 정도를 걷고 아침 7시에 학교 사무실에 와서 이 글을 쓰고 있네.
----------------------------------------
----------------------------------------
FDA News
FOR IMMEDIATE RELEASE
P06-79
June 12, 2006
Media Inquiries:
Kimberly Rawlings , 301-827-6242
Consumer Inquiries:
888-INFO-FDA
FDA Approves the First Drug for Seasonal Depression
The Food and Drug Administration (FDA) today approved Wellbutrin XL for prevention of major depressive episodes in patients with a history of seasonal affective disorder (SAD). This is the first drug approved for SAD. Wellbutrin XL (bupropion HCL extended release tablets) previously was approved for treatment of major depressive disorder.
SAD is characterized by recurrent major depressive episodes that usually coincide with the seasonal decrease of daylight during autumn and winter. The depressive episodes can last up to 6 months. Although patients with SAD may have depressive episodes during other times of the year, the diagnosis of seasonal affective disorder requires that the number of seasonal episodes substantially outnumber the non-seasonal episodes during the individual's lifetime.
A major depressive episode is defined as the presence of 5 or more of the 9 core symptoms of major depression for at least 2 weeks. The symptoms include: depressed mood; loss of interest; weight loss (or other weight or appetite changes); insomnia or hypersomnia; agitation or psychomotor retardation; fatigue; feelings of worthlessness or guilt; impaired concentration; suicidal thinking or behavior. One of the 5 symptoms must be either depressed mood or loss of interest in activities. Another essential feature of major depression is the presence of significant distress or impairment in social, occupational, or other important areas of functioning. A seasonal major depressive episode is defined by the identical features.
“Seasonal affective disorder can significantly impair the quality of life of patients with this condition,” said Dr. Steven Galson, Director for FDA’s Center of Drugs and Research. “Today’s approval can help patients with this condition to avoid the depressive symptoms and impaired functioning that typically affect them in the fall and winter.”
The effectiveness of Wellbutrin XL for the prevention of SAD episodes was established in 3 double-blind, placebo-controlled trials in adults with a history of major depressive disorder in autumn and winter. Treatment was initiated prior to the onset of symptoms in the autumn (September to November) and was discontinued following a two-week taper that began the first week of spring (fourth week of March). In these trials, the percentage of patients who were depression-free at the end of treatment was significantly higher for those on Wellbutrin XL than for those on placebo; for all 3 studies combined, the overall rate of patients depression-free at the end of treatment was 84 percent for those on Wellbutrin XL compared to 72 percent for those on placebo.
Wellbutrin XL’s labeling includes a “black box” warning concerning the increased risk of suicidal thoughts and behavior in pediatric patients treated with antidepressant medications. As with all antidepressants, Wellbutrin XL has a Medication Guide (MedGuide, or patient labeling) advising that pediatric patients on antidepressants should be watched closely for these serious symptoms. Important side effects to watch for with Wellbutrin XL, especially shortly after the initiation of the treatment, include agitation, anxiety and insomnia. Wellbutrin was safe and well tolerated by patients in the SAD trials.
It is important to note that Wellbutrin XL is indicated only for patients who meet strict diagnostic criteria of seasonal major depressive episodes. Such patients have a pattern of recurrent, clinically significant depressive symptoms with associated impairment of functioning. The clinician and patient should carefully assess the potential risks and benefits when considering treatment with Wellbutrin XL for SAD.
Wellbutrin XL is manufactured by GlaxoSmithKline.
------------------------------------------------
------------------------------------------------
내가 찾은, 위의 뉴스에 나오는 9개의 SAD증세 중 나는 7개의 증상(depressed mood; loss of interest; weight or appetite changes; hypersomnia; psychomotor retardation; fatigue; feelings of worthlessness; impaired concentration)을 보이네. 그렇다고 내가 SAD환자라는 이야기는 아니네. 내가 의사의 진단을 존중한다는 것을 또 이야기 하네. 한 자료에 의하면 미국에 약50만의 SAD환자가 있다고 하네.
위와 같은 연유로 내가 이 서신의 제목에 "D+SAD"[내가 작명]를 넣은 것이네. 지난 달 서울대병원 혈액검사 결과는 투약의 강도에 반비례하여 혈당과 체중은 다소 증가한 상태이네. SAD 탓일까?
좋은 조언 부탁하네. 작은 성의로 심장관련 파일 하나 보내네.
다음에 서울대병원 방문시에 내가 점심을 대접할 수 있도록 시간을 할애하여 주면 고맙겠네. 연락하겠네.
최창균